FluxMPS™ Dulbecco's Modified Eagle Medium (DMEM), Low Glucose, 25mM HEPES w/o L-Glutamine, Sodium Bicarbonate: 1X Liquid

FluxMPS™ Dulbecco's Modified Eagle Medium (DMEM), Low Glucose, 25mM HEPES w/o L-Glutamine, Sodium Bicarbonate: 1X Liquid

FluxMPS™ DCP-DMEMLH-QB1X is an MPS-grade, ultra-filtered DMEM Low Glucose + HEPES formulation engineered for microphysiological systems, organ-on-a-chip (OoC), and microfluidic tissue models. Processed through a Quadruple-stage filtration system (0.1 µm ×2 + 0.04 µm ×2), it delivers approximately 5× lower particulate counts than conventional 0.22 µm–filtered media. Formulation: [+] Low Glucose, [+] Sodium Pyruvate, [+] 25mM HEPES | [-] L-Glutamine, [-] Sodium Bicarbonate. HEPES (25 mM, pKa 7.3 at 37°C) provides robust CO₂-independent buffering.

• 0.04 µm final nano-filtration — sub-mycoplasma purity for microfluidic channels below 100 µm
• Quadruple-stage sequential filtration: 0.1 µm pre-I → 0.04 µm pre-II → 0.1 µm sterile-I → 0.04 µm final polish
• Endotoxin < 0.05 EU/mL (LAL, USP <85>)
• Formulation: [+] Low Glucose, [+] Sodium Pyruvate, [+] 25mM HEPES | [-] L-Glutamine, [-] Sodium Bicarbonate
• Ultrapure Type 1 water (18.2 MΩ·cm), ISO 13485:2016 QMS, ISO Class 5 fill
• 25 mM HEPES buffer (pKa 7.3 at 37°C) — pH-stable without CO₂ incubation
• Custom pH, salts, and nutrient adjustments available on request

Engineered where standard media fails

Conventional 0.22 µm–filtered media passes mycoplasma, subvisible particulates, and endotoxin fragments that clog microfluidic channels and corrupt sensor signals. FluxMPS™ eliminates these failure modes with four-stage sub-0.04 µm filtration. HEPES buffering eliminates CO₂ dependency for open-top chip architectures and atmospheric incubation.

Quadruple-stage filtration system

Four serial filtration stages reaching a final 0.04 µm polish under ISO Class 5 aseptic conditions — delivering sub-mycoplasma purity unavailable from any conventional 0.22 µm filtered media.

1. 1

   0.1 µm Pre-filtration I — Large Particulate Removal

   Removes large aggregates and particulates; protects downstream 0.04 µm membranes and chip geometries.

2. 2

   0.04 µm Pre-filtration II — Mycoplasma Barrier

   Retains mycoplasma (0.1–0.3 µm) and fine particulates — absent from standard 0.22 µm filtration.

3. 3

   0.1 µm Sterile-filtration I — Second-pass Redundancy

   Second-pass sterility redundancy; no breakthrough from Stage 1.

4. 4

   0.04 µm Sterile-filtration II — Final Polish

   Ultimate sub-mycoplasma polish; ISO Class 5 aseptic fill & finish.

Designed for next-generation cell models

FluxMPS™ DCP-DMEMLH-QB1X supports demanding platforms from single-channel microfluidic chips to multi-organ body-on-a-chip systems. The integrated 25 mM HEPES buffer makes it particularly suited to open-top microfluidic devices and atmospheric CO₂ environments.

Automated Bioreactors & Robotics

Optional 0.01 µm (10 nm) ultra-filtered variant available on request for automated bioreactor perfusion and robotic liquid handlers.

• Total Particulate Exclusion: 10 nm filtration removes nanoparticulate aggregates
• Valve & Sensor Protection: Eliminates micro-fouling of solenoid valves and inline optical sensors
• Extended Perfusion Stability: Consistent nutrient delivery over weeks-long culture

Inquiry Required: Contact support@diagnocine.com for the 0.01 µm variant.

Analytical release specifications

Every lot released against the full specification matrix. CoA: support@diagnocine.com.

Full composition (mg/L)

32 ingredients verified per lot with CAS numbers for full raw-material traceability.

Manufacturing & compliance

Every FluxMPS™ product is manufactured and released under a rigorous multi-layer quality system spanning raw materials, in-process controls, and final-product testing.

How DCP-DMEMLH-QB1X compares

FluxMPS™ DCP-DMEMLH-QB1X vs. conventional 0.22 µm–filtered DMEM Low Glucose + HEPES formulations.

Frequently asked questions

Common questions about FluxMPS™ DCP-DMEMLH-QB1X.

Supporting literature

Key peer-reviewed publications supporting MPS-grade, ultra-filtered media in organ-on-a-chip and microfluidic research.

1. Huh D, et al. Reconstituting organ-level lung functions on a chip. Science. 2010;328:1662–1668. doi:10.1126/science.1188302
2. Bhatia SN, Ingber DE. Microfluidic organs-on-chips. Nat Biotechnol. 2014;32:760–772. doi:10.1038/nbt.2989
3. Ham RG. Clonal growth of mammalian cells in a chemically defined, synthetic medium. Proc Natl Acad Sci USA. 1965;53:288–293. doi:10.1073/pnas.53.2.288
4. Novak R, et al. Robotic fluidic coupling and interrogation of multiple vascularized organ chips. Nat Biomed Eng. 2020;4:407–420. doi:10.1038/s41551-019-0497-x
5. Jang KJ, et al. Human kidney proximal tubule-on-a-chip for drug transport and nephrotoxicity assessment. Integr Biol. 2013;5:1119–1129. doi:10.1039/c3ib40049b
6. Schimek K, et al. Integrating biological vasculature into a multi-organ-chip microsystem. Lab Chip. 2013;13:3588–3598. doi:10.1039/c3lc50217a
7. Luni C, et al. High-efficiency cellular reprogramming with microfluidics. Nat Methods. 2016;13:446–452. doi:10.1038/nmeth.3832
8. Sung JH, et al. Microfabricated mammalian organ systems and their integration into models of whole animals and humans. Lab Chip. 2013;13:1201–1212. doi:10.1039/c3lc41017j